David A. Siegel Inozyme Pharma, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 24,300 shares of INZY stock, worth $70,227. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,300
Previous 29,600
17.91%
Holding current value
$70,227
Previous $132,000
3.79%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding INZY
# of Institutions
90Shares Held
53MCall Options Held
3.7KPut Options Held
5.8K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.67MShares$16.4 Million0.05% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$13 Million18.53% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$12.4 Million2.12% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.13MShares$11.9 Million0.38% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.8MShares$11 Million0.68% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $116M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...